Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

Clinical trials of imetelstat therapy have indicated that this telomerase inhibitor might have disease-modifying effects in a subset of patients with myelofibrosis (MF). The mechanism by which imetelstat induces such clinical responses has not been clearly elucidated. Using in vitro hematopoietic pr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Wang, Xiaoli, Hu, Cing Siang, Petersen, Bruce, Qiu, Jiajing, Ye, Fei, Houldsworth, Jane, Eng, Kevin, Huang, Fei, Hoffman, Ronald
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Myeloid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156882/
https://ncbi.nlm.nih.gov/pubmed/30242099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022012
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki